Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aurinia Pharmaceuticals Inc. (T:AUP)

Business Focus: Bio Therapeutic Drugs

Log in or join to add this stock to your watch list.
Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 1203-4464 Markham St
Tel: N/A
IR: See website
Key People
George M. Milne
Executive Chairman of the Board
Peter S. Greenleaf
Chief Executive Officer, Director
Dennis Bourgeault
Chief Financial Officer, Corporate Secretary
Michael R. Martin
Chief Operating Officer
Neil Solomons
Chief Marketing Officer
Celia Economides
Associate Vice President, Corporate Communications & Patient Advocacy
Robert B. Huizinga
Vice President - Clinical Affairs
Lawrence D. Mandt
Vice President - Regulatory and Quality
Business Overview
Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
Financial Overview
For the fiscal year ended 31 December 2018, Aurinia Pharmaceuticals Inc revenues increased 10% to $463K. Net loss decreased 9% to $64.1M. Revenues reflect United States segment increase of 15% to $345K. Lower net loss reflects Gain/Loss on Derivatives - Hedging decrease of 58% to $10M (expense), Interest income increase from $1M to $2.2M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.92 to -$0.76.
Employees: 39 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $631.58M as of Dec 31, 2018
Annual revenue (TTM): $0.62M as of Dec 31, 2018
EBITDA (TTM): -$73.31M as of Dec 31, 2018
Net annual income (TTM): -$86.11M as of Dec 31, 2018
Free cash flow (TTM): -$69.41M as of Dec 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 91,646,447 as of May 16, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization